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Abstract
High trait anxiety is a substantial risk factor for developing anxiety disorders and depression. While neuroinflammation
has been identified to contribute to stress-induced anxiety, little is known about potential dysregulation in the
neuroinflammatory system of genetically determined pathological anxiety or high trait anxiety individuals. We report
microglial alterations in various brain regions in a mouse model of high trait anxiety (HAB). In particular, the dentate
gyrus (DG) of the hippocampus of HABs exhibited enhanced density and average cell area of Iba1+, and density of
phagocytic (CD68+/Iba1+) microglia compared to normal anxiety (NAB) controls. Minocycline was used to assess the
capacity of a putative microglia ‘inhibitor’ in modulating hyperanxiety behavior of HABs. Chronic oral minocycline
indeed reduced HAB hyperanxiety, which was associated with significant decreases in Iba1+ and CD68+Iba1+ cell
densities in the DG. Addressing causality, it was demonstrated that longer (10 days), but not shorter (5 days), periods of
minocycline microinfusions locally into the DG of HAB reduced Iba-1+ cell density and attenuated hyperanxiety-
related behavior, indicating that neuroinflammation in the DG is at least partially involved in the maintenance of
pathological anxiety. The present data reveal evidence of disturbances in the microglial system of individuals with high
trait anxiety. Minocycline attenuated HAB hyperanxiety, likely by modulation of microglial activity within the DG. Thus,
the present data suggest that drugs with microglia-targeted anti-inflammatory properties could be promising as novel
alternative or complimentary anxiolytic therapeutic approaches in specific subgroups of individuals genetically
predisposed to hyperanxiety.
Introduction
Anxiety disorders are the most prevalent mental ill-
nesses affecting 284 million people worldwide in 20171.
The median age of onset for anxiety in various anxiety
disorders (11 years) is comparably earlier than in other
psychopathologies such as mood disorders (30 years)2.
Genetic predisposition to high trait anxiety has been
identified as a severe risk factor for anxiety disorders and/
or depression in later life3. New treatment approaches for
such pathologies are necessary4 to overcome problems
such as treatment-resistance, high suicide risk, and
treatment complications by comorbidities. However, this
requires a better understanding of underlying pathophy-
siological mechanisms5. Neuroinflammation has recently
been recognized as a potential mechanism contributing to
the onset and/or maintenance of psychiatric disorders, as
well as to resistance to current treatments6–8. Specifically,
presence of high inflammation and associated dysregu-
lated downstream pathways has been linked with treat-
ment resistance to antidepressants9, which are currently
used as first line treatment in many anxiety disorders.
Immune-targeting interventions have thus been proposed
as an alternative route in the treatment of psychiatric
disorders10. Neuroinflammation in the CNS involves key
factors, such as microglial migration and activation, and
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can exert beneficial or detrimental consequences within
an organism11.
The vast majority of clinical data in support of immune
dysregulation contributing to the pathophysiology of
anxiety-related disorders are restricted to those investi-
gating peripheral levels of cytokines, in panic disorder12,13,
post-traumatic stress disorder (PTSD)14, obsessive-
compulsive disorder (OCD)15,16, and generalized anxiety
disorder (GAD)13,17–20, with little attention given to social
anxiety thus far. Pro-inflammatory or “activated” micro-
glia secrete such cytokines and can phagocytose neural
progenitor cells or parts of neurons (e.g., synaptic prun-
ing), which shapes neuron circuits and can impact neu-
ronal connectivity21,22. Interestingly, brain connectivity
has been shown to be disturbed in early trait anxiety23.
Recent positron-emission tomography (PET) methods of
imaging translocator protein (TSPO) density as a marker,
positively correlates microglial activation in brain regions,
such as the hippocampus or dorsolateral prefrontal cor-
tex, with scores of state anxiety and apathy24, although
some have disputed TSPO as a specific marker for
microglia25. In line with such observations in humans,
alterations in microglia density or activation are reported
in various animal models of stress-induced anxiety or
depression, using e.g.: using unpredictable stress26 or
repeated social defeat27 as stressors. Such inflammatory
alterations are observed in key brain regions of the anxiety
circuitry, the most consistently reported region being the
hippocampus. Specifically, increased microglia density
and/or coverage in the hippocampus by various stressor
has been observed in rodents together with enhanced
state anxiety26,28–37. Minocycline is a lipophilic broad-
spectrum antibiotic drug with demonstrated anti-
inflammatory properties, as well as being a reputed
microglia activation ‘inhibitor’, and has been shown to
significantly ameliorate stress-induced state anxiety in
rodent models31,32,38–40. Thus far, there is a lack of studies
investigating brain region-specific inflammatory changes
in high trait anxiety, in the absence of specific stressors or
immune challenge. Thus, detailed knowledge on how
genetic predisposition to enhanced anxiety modulates the
neuroinflammatory system is lacking.
The current study, therefore, investigated evidence of
dysregulated neuroinflammation in the high anxiety
(HAB) mouse model, which exhibits high trait anxiety
compared to normal anxiety (NAB) controls. This phe-
notype is the result of a selective breeding approach of
CD-1 mice, according to anxiety scores assessed in the
elevated plus maze test41,42. Brain regions important in
the neurocircuitry of anxiety include the hippocampus,
amygdala, hypothalamus, and prefrontal cortex43, and
HAB mice show altered activity processing in such
anxiety-relevant networks and brain areas44,45. Interest-
ingly, similar brain areas are likely candidate regions to
show links between inflammatory and brain activity
alterations, including the hippocampus, amygdala, and
prefrontal cortex (e.g., refs. 32,46). The main aims of this
study were to investigate whether mice with high trait
anxiety display alterations in the brain microglia system as
compared to normal anxiety (NAB) control mice, and
whether the aberrant anxiety behavior can be modulated
by a drug possessing anti-inflammatory properties by
targeting microglia, minocycline.
Materials and methods
For detailed information, see Supplementary Materials
and Methods.
Animals
Male HAB and NAB mice were selectively inbred for
their specific anxiety-related behavior at the Department of
Pharmacology, Innsbruck Medical University, Innsbruck
(Austria), as described previously47. HABs and NABs
(11-22w) had access to food pellets and water ad libitum,
and were group-housed in individually ventilated cages
under standard laboratory conditions (12:12 light/dark
cycle with lights on at 07:00 h, 22 ± 2 °C, 45–60% humid-
ity). All experiments were approved by the Austrian Ani-
mal Experimentation Ethics Board (Bundesministerium für
Wissenschaft Forschung und Wirtschaft, Kommission für
Tierversuchsangelegenheiten) and were in compliance
with international laws and policies.
Minocycline treatment
Minocycline dosages for systemic and local adminis-
tration were chosen according to previous studies show-
ing effects on microglia and behavior26,31. Mice received
an average oral minocycline (Sigma-Aldrich) dosage of
40 mg/kg/day for 28 d. For local microinjections, mino-
cycline (20 µg/μl) was infused bilaterally into the DG once
daily, for 5 d (shorter period) or 11 d (longer period).
Stereotaxic surgery and microinjections
HAB mice were placed in a stereotaxic frame (David
Kopf Instruments) under 2% isoflurane anesthesia. Guide
cannulas (25 gauge, 8 mm in length) were implanted
1 mm above the left and right DG (AP: −2.18 mm, ML:
±1.40 mm, DV: −1.2 mm from Bregma). Following sur-
gery, mice were single-housed and received buprenor-
phine (0.5 mg/kg s.c.) and meloxicam (0.5 mg/kg p.o. via
drinking water) for analgesic care for up to 3 d, and were
allowed to recover for 7 d. Either saline or minocycline
solution (0.25 µl/hemisphere) were infused bilaterally at a
speed of 0.1 µl/min. The histological verification of the
localization of the microinfusion probes revealed one
animal with misplaced cannulae that was subsequently
removed from the further behavioral or microglial
analysis.
Rooney et al. Translational Psychiatry          (2020) 10:256 Page 2 of 10
Behavioral testings
Levels of anxiety-related behavior of mice were assessed
in the light/dark (LD) test, open field test, and the elevated
plus maze (EPM) test according to established and pre-
viously used protocols47,48.
Immunohistochemistry
Mice were sacrificed 2 h following the LD test. Coronal
brain sections were incubated with primary antibodies,
goat anti-Iba1 (1:500 Abcam, #ab107159) and rabbit anti-
CD68 (1:300 Abcam, #ab125212) or rabbit anti-TMEM119
(1:300 Abcam, #ab209064) followed by incubation with
respective fluorescent-labeled secondary antibodies using
established immunohistochemistry protocols47.
Immunofluorescence microscopy
In one section per mouse, images of both the left and
right DG of the hippocampus (Interaural 1.98mm,
Bregma −1.82mm), representative area consisting of
polymorphic, hilus and granular cell layers, were taken
using a fluorescent microscope (Olympus, Austria),
applying a ×4 objective to locate specific brain structures
and a ×20 objective for quantitative analyses. Additional
images were taken of the basolateral amygdala (BLA),
nucleus accumbens (NAcc), medial prefrontal cortex
(mPFC), cingulate cortex, and paraventricular nucleus
(PVN) of the hypothalamus. For oral minocycline
experiment, both the left and right DG (−1.82mm from
Bregma) was assessed. For intra-DG minocycline experi-
ment, Iba-1+ cells were counted at the level of (−2.80mm
from Bregma) due to significant tissue tear at the level of
−1.82mm that was observed in almost all animals.
Quantification of immunopositive-cells was assisted by an
image analysis system (cellSens Dimension; Olympus).
Statistical analysis
Data analyses were performed with GraphPad Prism
8.0 software (GraphPad Software Inc., USA), following the
exclusion of outliers identified by Grubb’s test. Data were
analyzed by unpaired Student’s t-test (two-tailed). Corre-
lational analysis was evaluated by Pearson’s co-efficiency
analysis. Significance was set at p < 0.05, and data are
presented as means ± standard error of the mean (S.E.M.).
Results
Microglia alterations in the brains of high trait anxiety
mice
In hyperanxious HAB mice and normal anxiety NAB
controls, Iba1+ microglia were imaged and visualized in
various anxiety-related brain regions. Among all regions
analyzed, the DG, the neurogenic niche of the hippo-
campus, showed the most robust Iba1 alterations (Fig. S1).
Our previous studies have shown altered neuronal activity
and reduced neurogenesis associated with anxiety in the
DG of HAB mice and rats45,47, thus compounding the DG
as the main candidate region of interest. Image J-assisted
analysis revealed that the density (p < 0.001, t(16)= 4.311)
and average cell area (p < 0.01, t(11)= 3.695) of Iba1+
microglia was significantly higher in the dorsal DG (dDG)
of HAB mice, compared to NAB mice (Fig. 1a, b). Using
Image J-generated total area (µm2) of Iba1-positive
staining, this was divided by the total area of the image
(µm2) and expressed as a percentage (% Iba1 coverage),
which can be an index used to account for simultaneous
alterations in cell density and morphology49. The per-
centage of Iba1 coverage was enhanced in the dDG of
HAB (p < 0.001, t(16)= 4.288; Fig. 1a). In the ventral DG,
the density (p < 0.05, t(16)= 2.647), average cell area (p <
0.05, t(16)= 2.382) and % coverage (p < 0.05, t(16)= 2.427)
of Iba1+ microglia was also significantly increased in
HAB compared to NAB (Figs. S1 and S2a). In regards to
additional brain regions, there was an augmentation of
average Iba1+ cell area (p < 0.01, t(11)= 3.304) and % Iba1
coverage (p < 0.05, t(11)= 2.395) observed in the medial
prefrontal cortex, but changes in density did not reach
statistical significance (p > 0.05, t(11)= 1.795) (Fig. S2b).
There were no significant differences in other brain
regions investigated including the cingulate cortex, BLA,
PVN, and NAcc (Fig. S1).
Since Iba1 is a constitutive marker for myeloid cells, we
used TMEM119 as an additional marker for the dis-
crimination of resident microglia from potentially infil-
trating blood-derived macrophages50. Our findings
revealed that the vast majority of Iba1+ cells were positive
for TMEM119 (98.91 ± 0.24%) in the DG of HAB mice,
indicating the vast majority of the enhanced Iba1+ cells
represents a true microglia population (Fig. S3). Specific
cellular markers expressed on microglia are important
indicators of microglial activity in the central nervous
system (CNS), thus we next aimed to determine the
expression levels of the phagocytosis/antigen-presenta-
tion marker CD6851,52 in the DG. There was an increased
density of co-labeled Iba1+CD68+ cells in the granular
cell layer of HAB, compared to NAB (p < 0.05, t(16)=
2.330; Fig. 1a, c), indicating a potential increase in
microglial phagocytic activation in this region in HAB
compared to NAB mice.
Anxiety-like behavior of HAB and NAB mice was correlated
with microglia alterations in the DG
Behavioral testing in the LD test confirmed an enhanced
anxiety-related behavior in HABs, compared to NAB
controls (Fig. 2a), as HAB mice spent less time in the
brightly lit compartment of the testing arena (p < 0.01,
t(15)= 3.146), and also entered the light arena less often
(p < 0.01, t(8)= 3.484), as demonstrated previously
47,53. To
gain evidence linking behavior and neuroinflammatory
parameters, we asked whether alterations in hippocampal
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Fig. 2 Anxiety behavior is correlated with microglia alterations in the dentate gyrus (DG) of HAB mice. HAB mice display hyperanxious
behavior in the light/dark test, whereby HAB mice spent significantly less time in the light arena and entered the light arena less often, compared to
NAB (a). In HAB and NAB, Iba1+ microglia average cell area and Iba1+ cell density in the DG was negatively correlated with behavioral scores in the
light/dark test; time spent in and entries to the light arena, respectively (b). *p < 0.05, Pearson’s correlation, r and p values indicated in the plots.
n= 7–11.
Fig. 1 Microglial alterations in the dentate gyrus (DG) of HAB mice. Hyperanxious HAB mice show significantly enhanced Iba1+ cell density,
Iba1+ cell area average, and percentage of coverage by Iba1+ cells of the dorsal DG, compared to NAB controls (a). Representative images of Iba1
(red) and DAPI (blue) staining in the DG of HAB and NAB mice, inset is microglia size example (b) scale bar 100μm. Iba1+ CD68+ cell density is
enhanced in the granular cell layer of the DG in HAB (a). Representative images of Iba1 (red) and CD68 (green) staining in the DG of HAB and NAB
mice (c), scale bar 50 μm. Data are presented as mean ± SEM. n= 7–11. *p < 0.05, **p <0.01, ***p < 0.001 vs. NAB (Student’s t - test).
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microglia are associated with symptom severity of trait
anxiety in HAB and NAB groups. Indeed, the average
microglia area size in the DG was negatively correlated
with time spent in the light (p < 0.05, r=−0.47), and
microglia density in the DG was negatively correlated with
entries to the light (p < 0.05, r=−0.55) (Fig. 2b), indi-
cating that enhanced microglial density or size within the
DG correlates with enhanced anxiety in the LD test.
Attenuation of hippocampal microglia activity and
anxiety-related behavior in HAB mice by chronic oral
minocycline treatment
Minocycline was administered in order to substantiate
the association between neuroinflammation and high trait
anxiety, and to gain information whether the observed
elevation in microglia activity in the DG contributes to or
represents an expression of insufficient counter-
regulation to pathological hyperanxiety. In HAB mice,
chronic oral minocycline treatment reduced the enhanced
Iba1+ microglia density (p < 0.001, t(18)= 8.741), average
cell area size (p < 0.001, t(18)= 6.840) and percentage of
coverage of the dDG (p < 0.001, t(18)= 8.486) compared to
vehicle treatment (Fig. 3a). Additionally, there was an
attenuation of co-labeled Iba1+CD68+ microglia density
in the granular cell layer of the dDG (p < 0.001, t(19)=
6.266; Fig. 3a, b) in minocycline- vs. vehicle-treated HAB
mice. Therefore, we next asked whether minocycline-
induced attenuation of microglia was associated with a
reduction in hyperanxiety. Indeed, we found that mino-
cycline reduced enhanced anxiety-like behavior in HABs,
as in the light–dark test, minocycline-treated HAB mice
displayed an increased amount of time spent in (p < 0.05,
t(21)= 2.612), number of entries to (p < 0.05, t(21)= 2.415),
and distance traveled in (p < 0.05, t(21)= 2.815), the light
arena compared to vehicle-treated HABs (Fig. 3c).
Longer, but not shorter, periods of intra-DG minocycline
treatment attenuated hyperanxiety of HAB mice
accompanied by reduced microglial density in the DG
In order to investigate a direct link between trait anxiety
behavior and microglial activity in the DG, minocycline
was microinjected bilaterally into the DG of HAB for a
shorter (5 days, Fig. 4a) or longer period (11 days, Fig. 4b).
To test for acute effects, animals were subjected to the
open field test at 2 h following the first microinjection.
This test was chosen here instead of the LD test in order
Fig. 3 The impact of chronic oral minocycline treatment on microglia in the dentate gyrus (DG) and anxiety-related behavior of HAB mice.
HAB mice treated with oral minocycline (Mino) showed reduced Iba1+ cell density, Iba1+ cell area average, percentage of coverage by Iba1+ cells of
the DG, and CD68+Iba1+ microglia density, compared to untreated HAB (a). Representative images of Iba1 (red) and CD68 (green) staining in the DG
of HAB and HAB Mino groups (b), scale bar 50 μm. HAB mice show reduced anxiety behavior in the light/dark test following minocycline treatment,
whereby HAB Mino group spent significantly more time in, more entries to, and more distance traveled in, the light arena compared to untreated
HAB (c). Data are presented as mean ± SEM. n= 10–13. *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t-test).
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to avoid habituation effects upon second test exposure
along with a possible loss of sensitivity in detecting
anxiolytic effects54. N12o significant differences were
found in both experiments (p > 0.05, Fig. S4), thus indi-
cating no acute effect of minocycline on anxiety-related
behavior. After repeated administration, mice of all
groups were subjected to the LD test at 2 h following the
last microinjection. Mice treated for 5 days showed no
significant differences in time spent in entries to, and
distance traveled in, the light arena, compared to the
vehicle group (p > 0.05) (Fig. 4c). This lack of effect on
anxiety-related behavior was paralleled with no changes in
the Iba-1+ cell density n the DG (Fig. 5b).
In contrast, longer (10 days) intra-DG minocycline-
treated HAB displayed significantly increased time spent
in (p < 0.05, t(12)=−2.470), entries to (p < 0.05, t(12)=
−2.186), and distance traveled in (p= 0.08, t(12)=
−1,889), the light arena (Fig. 4d) compared to controls.
On the next day the anxiolytic-like effect of long-term
intra-DG minocycline was explored in an additional test
to assess anxiety-related behavior, the elevated plus maze.
Again, we obtained evidence of reduced anxiety-related
behavior of long-term intra-DG minocycline-treated HAB
as indicated by a significant increase in percentage of
entries to the open arm of the EPM (p < 0.05, t(11)= 2.524)
(Fig. S5), thereby validating the results of the LD test.
Furthermore, in association with successful anxiolysis,
longer periods of intra-DG minocycline treatment exerted
a significant reduction in Iba-1+ cell density in the DG of
HABs (Fig. 5b, c), compared to vehicle-treated HABs.
Discussion
The current results show that HAB mice, possessing a
genetic predisposition to high trait anxiety, display clear
signs of a central immune dysregulation as indicated by
an increased density of microglial phagocytic activity in
the DG. Minocycline, a tetracycline antibiotic demon-
strating significant anti-inflammatory properties55, par-
tially improved the revealed microglia dysregulation
in the CNS, upon systemic administration. These
Fig. 4 Impact of local application of into the dentate gyrus (DG) on anxiety-like behavior of HAB mice. Experimental timelines, shorter period
(5 d) (a) and longer periods (11 d) (b) of minocycline infusions. Following 5 days of intra-DG minocycline or saline daily infusions, HAB groups showed
no significant differences in the light/dark test (c). Following 10 days of intra-DG minocycline daily infusions, HAB displayed increased time spent in,
entries to, and distance traveled in, the light arena of the light/dark test (d), compared to intra-DG saline HAB. Data are presented as mean ± SEM.
n= 7–11, *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t-test).
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minocycline-induced effects on microglia were associated
with clearly attenuated hyperanxious behavior in HABs.
Furthermore, modulating microglia activity locally in the
DG, via long-term minocycline microinjection, was also
sufficient to attenuate hyperanxiety in HAB. Together,
the current findings suggest that central inflammatory
disturbances are evident in individuals with high trait
anxiety, even in the absence of known triggers of
inflammation such as chronic stress56,57. Furthermore,
inflammation-targeting approaches, such as inhibitors of
microglia ‘activation’, could serve as alternative or com-
plementary treatment approaches in patient sub-groups
presenting with genetically determined hyperanxiety.
The role of neuroinflammation in trait anxiety has
remained virtually unexplored, with the exception of one
study comparing varying levels of anxiety in mice, how-
ever in unrelated mouse strains that differ not only in
anxiety, but also in a variety of other behaviors58.
Although this study did not investigate differences in
resident microglia population, it showed that an increased
ratio of ‘M1 (pro-inflammatory)’ to ‘M2 (anti-inflamma-
tory)’ microglia was present in whole brain homogenates
of a high anxiety DBA/2 J strain. Here we compare
microglia across various brain regions of innate high- and
normal-anxiety mice selectively bred from the same
genetic CD-1 background, thus reducing between-strain
differences. Our findings reveal that even in the absence
of immune challenge or specific stress paradigms, HAB
mice exhibiting high trait anxiety showed increased
microglia density, cell size and coverage specifically in the
DG of the hippocampus, a brain region implicated in
various functions including anxiety, learning and mem-
ory43,59, indicating a contributing role for neuroin-
flammation in the disruption of these processes.
Enhanced microglia density and activity in the hippo-
campus of HABs is in line with evidence from a human
PET study in which microglial activation (as measured by
TSPO binding capacity) in the hippocampus was posi-
tively correlated with anxiety scores24. Furthermore,
anxiety- and depression-like behaviors induced by chronic
mild stress57 or postnatal stress60 are associated with
increased microglial ‘activation’ in the hippocampus, and
acute unpredictable stress increases microglia density in
the DG of mice26. Microglia are regulators of neurogenic
activity61 and suppressed neurogenesis following acute
stress has been shown to be accompanied by increased
presence of microglia in the DG30. In that respect it is
interesting to note that neurogenesis and functional
integration of newly born neurons are impaired in the DG
of HAB47 and neuronal activation in the DG was found to
be blunted (c-Fos expression in response to different
challenges)45,47. These observations together with the
current data indicate a link between reduced hippocampal
neurogenesis/connectivity and enhanced microglial den-
sity/activation in high trait anxiety HAB, which will be
addressed in future studies.
Relatedly, microglial phagocytic activity seems to be
enhanced in the DG of hyperanxious HAB as indicated by
Fig. 5 Impact of local application of minocycline into the dentate gyrus (DG) on Iba-1 density in HAB mice. Schematic illustration of the sites
of DG hits (a). Following 5 days of intra-DG minocycline or saline daily infusions, HAB groups showed no significant differences in the Iba-1 density
(b). Following 10 days of intra-DG minocycline daily infusions, HAB showed reduced Iba-1 density (b). Representative images showing Iba-1+ cells in
the DG following long-term intra-DG vehicle/ minocycline administration (c). Data are presented as mean ± SEM. n= 7–11, *p < 0.05 (Student’s t-test).
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an increased CD68+ microglia density, compared to NAB
controls. Along this line, CD68 immunoreactivity has
been shown to be enhanced in the hippocampus of
chronic unpredictable mild stress-exposed rats displaying
increased anxiety behavior28, and also in the DG of stress
animal models (early life stress;29 forced swim stress30).
Thus the involvement of enhanced hippocampal CD68
expression, and thereby microglial phagocytic activity
(CD68+Iba1+), previously demonstrated in state anxiety
is now also supported in trait anxiety model. Taken
together, these studies indicate that microglia state and
function contribute to the maintenance of both state and
trait anxiety.
We found that the enhanced DG microglial density in
HAB mice can be normalized with chronic systemic min-
ocycline administration, which was in association with
significant anxiolysis in these hyperanxious mice. While the
present study indicates that chronic minocycline (28 d) can
attenuate trait anxiety in HAB mice in the light/dark test, a
shorter minocycline treatment protocol (17 d) did not
attenuate hyperanxiety in HAB rats62, assessed in the light/
dark test or EPM. This might be caused by the difference in
treatment duration, but as well could reflect interspecies
differences. In line with the latter, HAB mice have been
shown to be SSRI-insensitive63, while HAB rats respond to
some, but not all, SSRIs62,64. Furthermore, rat and mouse
HAB lines were generated independently by selective
breeding, therefore, it is likely, that HAB mice/rats may
reflect differing aspects of anxiety disorders. In support of
this idea, pilot studies in humans have shown that mino-
cycline as monotherapy or in combination with anti-
depressants/antipsychotics leads to moderate improvement
in anxiety scores of patients with treatment-resistant
depression65, obsessive compulsive disorder66, schizo-
phrenia67 or Fragile-X syndrome68. Along these lines,
investigation of the effectiveness of minocycline in the
treatment of chemotherapy-induced anxiety and depres-
sion in breast cancer patients is currently registered
(NCT02203552). Also recently, another clinical trial has
been initiated to assess the effect of minocycline as an
adjunctive treatment (to standard antidepressants) for
treatment-resistant depression and comorbid GAD69.
The minocycline-induced attenuation of hyperanxiety
in HABs was also associated with a significant reduction
of the enhanced CD68+ microglia population in the DG,
which indicates that minocycline exerts its anxiolytic
effects potentially by reducing microglial phagocytic
activity in this region. Along these lines, the administra-
tion of coenzyme Q10, an antioxidant and anti-
inflammatory compound, was shown to decrease the
stress-induced increase in hippocampal CD68 immunor-
eactivity in a dose-dependent manner, in association with
a decrease of anxiety behavior28. Together, such drug
studies support an association between reduced brain
CD68 expression and attenuated anxiety.
Interestingly, microglial differences between HAB and
NAB were heterogenous in different brain areas. While
such differences were minor or missing in brain areas such
as nucleus accumbens, PVN or BLA, we found increased
Iba1+ microglia cell area size, coverage and density also in
the mPFC (medial prefrontal cortex) of HAB mice. In
contrast, a recent study in rats showed lower Iba-1+ cell
density within the mPFC of HAB vs NAB62. A reason for
this discrepancy could be that Schmidtner and colleagues62
exposed HAB rats to multiple challenges involving LD test,
EPM test, pre-swim session, forced swim test, while HAB
mice in the current study were exposed to only one chal-
lenge (LD test). Furthermore, the mPFC is a heterogeneous
cortical structure composed of different subregions
(including the prelimbic and infralimbic cortex) which are
differentially involved in anxiety-like behavior70. Further-
more, microglial cells are distinctly expressed in a layer-
specific manner within these subregions which are again
differentially regulated by stressors71. Therefore, regional
differences as well as single/multiple stressors could
account for the discrepancy in microglial density in both the
studies. Nevertheless, both these studies across two differing
rodent species suggest that besides the DG, the mPFC
represents an additional inflammatory focal point in the
CNS of individuals predisposed to trait anxiety and it will be
also interesting to see how anxiety can be modulated by
interfering with the inflammatory system within the mPFC.
Evidence of a possible causal link between enhanced DG
microglia density and trait anxiety behavior is provided in
the current study by pharmacologically targeting local DG
microglia (and possibly other CNS cells) with minocycline
microinjection. This reduced DG Iba-1+ expression and
hyperanxiety in HAB, as measured by the LD test. Notably,
only when minocycline was able to reduce DG microglia in
a longer 10 d (but not in a 5 d) treatment protocol,
anxiolysis was observed, indicating that it is likely neces-
sary to recruit mechanisms that require more chronic
interaction, e.g.: enhancing neuroplasticity and/or neuro-
genesis in this brain area. However, the possibility that
local infusion of minocycline to the DG could also exert
effects on microglia and/or cytokines in other brain
regions, as well as immune cells in the periphery cannot be
fully excluded. Only few studies thus far have investigated
the effects of local application of minocycline on anxiety or
anxiety-related behaviors. Acute stress-induced anxiety in
rats, induced by single prolonged stress, was shown to be
attenuated by application of intra-hippocampal minocy-
cline31. In general, such studies altering anxiety behavior
by directly modulating microglia activity in a brain region-
specific manner support the current findings, which sug-
gest neuroinflammation in the DG of the hippocampus as
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a mechanism contributing to the maintenance of patho-
logical anxiety.
In conclusion, this study describes brain region-specific
microglial alterations in a mouse model of high trait
anxiety. These alterations were sensitive to the microglia-
modulating drug, minocycline. Specifically, chronic sys-
temic or local intra-DG minocycline was sufficient to
reduce microglial upregulation and hyperanxious beha-
vior in this mouse model. Thus, treatments including
drugs72 or also antibody approaches73 targeting microglia
and/or additional inflammatory mechanisms represent
potential strategies for a subgroup of individuals with
high trait anxiety who are at a risk of developing neu-
ropsychiatric disorders such as anxiety disorders or
depression.
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